Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EpiCept, a specialty pharmaceutical company, has appointed Collier Smyth, former senior vice president of medical strategy - oncology at Bristol-Myers Squibb Company to its board of directors.
Subscribe to our email newsletter
Prior to his recent retirement from Bristol-Myers, Dr Smyth led oncology medical affairs in the US, including the US life-cycle development of paclitaxel, carboplatin and ifosfamide.
Prior to joining Bristol-Myers, Dr Smyth served as vice president of medical affairs with American Oncology Resources, now US Oncology, where he was responsible for establishing the medical strategic priorities of the country’s largest oncology physician group practice. Dr Smyth also serves on the board of directors of Ariad Pharmaceuticals.
Robert Savage, chairman of the board of directors at EpiCept, said: “We are delighted that Dr Smyth has decided to join our board of directors. It is a tremendous opportunity to be able to bring someone with his wealth of expertise and experience in the field of oncology to the EpiCept board, particularly as the company prepares for the launch in Europe of Ceplene with a commercial partner.”